MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$31,103K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-62,845 -
Depreciation
555 1,247
Noncash operating lease expense
973 2,030
Stock-based compensation
6,625 13,825
Accretion on marketable securities
-560 -1,360
Net loss
--78,729
Other, net
1 57
Prepaid expenses and other current assets
1,652 461
Other long-term assets
-20 306
Accounts payable
-344 750
Accrued expenses and other liabilities
1,604 -4,988
Operating lease liabilities
-245 -1,594
Deferred revenue
-53,811 -8,573
Net cash used in operating activities
-30,952 -78,216
Purchase of property and equipment
151 675
Sales and maturities of marketable securities
65,965 119,150
Purchases of marketable securities
18,337 71,100
Net cash provided by investing activities
47,477 47,375
Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under espp
2,541 583
Net cash provided by financing activities
2,541 583
Net change in cash, cash equivalents and restricted cash
19,066 -30,258
Cash and cash equivalents at beginning of period
72,097 -
Cash and cash equivalents at end of period
60,905 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics, Inc. (TNGX)